
Introduction Topiramate is efficacious for treating alcohol use disorder (AUD), but treatment response varies considerably. To advance precision treatment, we used machine-learning methods integrating clinical trial and genetic data to estimate expected response to topiramate.Methods Random forest (RF) regression models were used to estimate expected topiramate response using randomized clinical trial data from 278 participants and 23 pre-treatment features: four alcohol polygenic risk scores (PRS), nine alcohol drinking measures, and 10 clinical and sociodemographic variables. RF importance scores quantified each feature's contribution to predictive performance. Likely Responders (LRs) were identified using quintiles of predicted treatment response and counterfactual placebo response, with LRs defined as quintiles in which randomized trial data demonstrated topiramate superiority over placebo. Variable Selection Using Random Forests (VSURF) was used to eliminate less informative and redundant predictors.Results Two pre-treatment drinking measures consistently had the highest importance scores across all VSURF levels. The final parsimonious model retained three predictors: average drinks per day, percent heavy drinking days, and the PRS for "Time Until Relapse," with bias-corrected R2 = 0.30. LRs comprised the top four predicted response quintiles (80% of the sample) across models. Compared with unlikely responders, LRs had lower baseline drinking severity and higher "Time Until Relapse" PRS.Conclusions The "Time Until Relapse" PRS contributed meaningfully to estimating expected response, LR stratification, and observed topiramate treatment effects, although pre-treatment drinking measures remained the strongest predictors. These findings support incorporation of pharmacogenomic markers into machine-learning models to advance precision prescribing for AUD.
Abstract Aim Sleep is critical to health, yet its relationship to metabolic dysfunction (MD) in alcohol use disorder (AUD) remains understudied in US clinical populations. Methods 1359 participants were recruited through the Natural History Protocol at the National Institutes of Health and categorized into four groups: healthy controls (HC), individuals with MD only (metHC), individuals with current AUD without MD (AUD), and individuals with both current AUD and MD (metAUD). Sleep was assessed using the Pittsburgh Sleep Quality Index (PSQI). Multinomial logistic regression models were used to test associations between sleep metrics and group status, adjusting for age, race, and sex (Model 1), and additionally for education, income, and smoking status (Model 2). Additional models examined sleep outcomes by MD severity (mild, <3; severe, ≥3 criteria) among AUD. Results Thousand two hundred twenty participants were included: 155 HC, 397 metHC, 77 AUD, and 591 metAUD. Adverse sleep outcomes were associated with increased odds of metHC, AUD, and metAUD groups compared to HC, with the strongest associations observed for metAUD across multiple PSQI domains. Each one-category increase in sleep disturbance was associated with an eleven-fold increase in odds of metAUD relative to HC (OR: 11.71, 95% CI, 6.90–19.86). Associations remained significant in Model 2. Sleep disturbance and daytime dysfunction were also associated with increased odds of severe MD compared to AUD-only (false discovery rate < 0.05). Conclusions Adverse sleep outcomes were associated with increased odds of co-occurring MD in AUD, highlighting the clinical relevance of monitoring both sleep and metabolic health and the need for targeted intervention in this population.
Abstract Aim To clarify the association between parental alcohol consumption and congenital genitourinary abnormalities (CGAs) in offspring. Methods Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, we conducted a systematic review and meta-analysis of cohort and case–control studies to examine the association between parental alcohol consumption during the periconception period and the risk of CGAs and its phenotypes, and to explore potential dose–response patterns. This review was not registered in PROSPERO. Results Twenty-seven studies involving 52 285 malformed cases and 121 772 controls were included. Maternal alcohol consumption was associated with lower odds of cryptorchidism (OR 0.87, 95% CI 0.80–0.95, P = .001) and higher odds of hypospadias (OR 1.16, 95% CI 1.08–1.26, P < .001), but the association was not significant when the phenotypes were pooled (OR 1.03, P = .55). In the dose–response analysis, the association between maternal alcohol intake and cryptorchidism was non-linear. The curve suggested a change at ~60 g/week; however, this estimate was based on a limited number of studies and should not be regarded as an established threshold. Conclusions Maternal average alcohol consumption was associated with higher odds of hypospadias, whereas moderate-to-severe alcohol consumption was associated with higher odds of cryptorchidism in a non-linear manner. Low-dose maternal alcohol consumption was not associated with cryptorchidism, but the inverse association observed for overall maternal alcohol consumption should be interpreted cautiously. Although the observed pattern may be consistent with a cumulative effect, we still recommend complete abstinence from alcohol during the periconceptional period and pregnancy.
Abstract Aims Plasma exchange (PLEX) and low-dose steroid improve survival in alcohol-related acute on chronic liver failure (A-ACLF) patients. In this study, we aimed to objectively assess its effect on nutritional parameters and quality of life (QoL) in survivors. Methods Alcohol-related ACLF (as defined by Asia Pacific Association of Study of Liver) patients treated with PLEX and low-dose steroid (August 2023–May 2025) were serially assessed prospectively for nutritional status, anthropometry, sarcopenia, frailty, and QoL. Centrifugal low-volume PLEX, with low-dose steroid was done as per protocol (PMID: 37975044). Results Forty-eight A-ACLF patients [males: 48; age: 40 (27–68) years; median (range); discriminant function: 103 (43–206); MELD score: 31 (22–50)] treated with PLEX and low-dose steroids were studied. At baseline, all 48 patients had malnutrition (severe: 15, moderate: 27, mild: 6), the majority had sarcopenia (38 patients, 79%), were frail [42 patients, 87.5%; liver frailty index (LFI): 4.9 (4.3–6.7)], and had poor QoL [Chronic Liver Disease Questionnaire (CLDQ): 3.4 (2.6–4.3)]. On follow-up (3–6 months, n = 25), there was improvement in nutritional parameters—nutrition status [moderate–severe impaired nutrition: 19 patients (76%) to 9 (36%), P-value < .02]; hand grip strength [19.4 (7.6–31) kg to 21.5 (8.7–31.3) kg, P-value .012]; muscle mass [skeletal muscle index: 6.3 (2.7–7.4) to 6.9 (4.2–8.8), P-value .05]; severe sarcopenia [20 (80%) to 7 (28%), P-value .001]; frailty [LFI: 4.7 (4.3–6.1) to 4.5 (3.5–6.6), P-value < .001]; QoL [CLDQ: 3.5 (2.6–4.4) to 5.7 (3.5–6.8), P-value <.001]; and MELD: 30 (23–43) to 17 (7–30); P-value: .05; at baseline and at follow-up, respectively. ACLF reversal was observed in 9/25 (36%) patients. Conclusions In A-ACLF patients, survival after PLEX and low-dose steroid is associated with improvement in nutritional parameters and QoL.
Aims To examine the effects of cannabidiol (CBD) on psychophysiological responding and risky decision-making in individuals with alcohol use disorder (AUD). Methods In a double-blind, placebo-controlled crossover trial, 18 participants with AUD completed the Columbia Card Task (CCT) following administration of CBD and placebo. Skin conductance responses (SCR) and high-frequency heart rate variability (HF-HRV) were assessed as indices of autonomic responding during task performance. Risk-taking was indexed by the number of cards selected on the CCT. Results CBD did not significantly affect SCR (P = .16, p(BH) = .326) or risky decision-making on the CCT (P > .63, p(BH) = 0.67). However, CBD significantly increased HF-HRV (beta = 0.53, SE = 0.19, P = .005; p(BH) = 0.020). There was no evidence that the relationships between HF-HRV or SCR and risky decision-making differed between CBD and placebo conditions (drug & times; HF-HRV: P = .92; drug & times; SCR: P = .958; both p(BH) = .958).Discussion CBD increased HF-HRV but did not significantly alter SCR, risky decision-making, or the relationship between autonomic responses and risky decision-making. These findings suggest that CBD influences autonomic responding during task performance, although the functional significance of this effect remains uncertain. The modest sample size and relatively healthy, non-treatment-seeking sample may have limited the ability to detect broader physiological and behavioural effects.